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Abstract  
Background: Central nervous system lymphoma (CNSL) is diagnostically challenging. The 
identification of reliable and easy to measure biomarkers is desirable to facilitate diagnosis. Here, we 
evaluated the value of cerebrospinal fluid (CSF) osteopontin (OPN) as a diagnostic biomarker for 
CNSL.  
Methods: OPN concentrations in CSF from 37 patients with CNSL (29 with primary CNSL and 8 
with secondary CNS involvement of systemic lymphoma) and 36 controls (6 patients with 
inflammatory CNS disease other than multiple sclerosis [MS], 8 with MS, 9 with glioblastoma [GBM] 
and 13 healthy controls) were determined using an enzyme-linked immunosorbent assay. Non-
parametric tests and receiver operating characteristic (ROC) curves were performed for determination 
of diagnostic accuracy.  
Results: Median CSF OPN level in all CNSL patients was 620 ng/mL and higher than in patients with 
inflammatory CNS disease (356 ng/mL); P < .05, MS (163 ng/mL); P < .01, GBM (41 ng/mL); P < 
.01, or healthy controls (319 ng/mL); P < .01. The area under the ROC curve was .865 (95% 
confidence interval [CI] .745-.985) for differentiating CNSL and patients with inflammatory CNS 
disease; .956 (95% CI .898-1.000) for CNSL and MS patients; .988 (95% CI .964-1.000) for CNSL 
and GBM patients, and .915 (95% CI .834-.996) for CNSL patients and healthy controls. In 
multivariate analysis, high CSF OPN level was associated with shorter progression-free (HR 1.61, 
95% CI 1.13-2.31, P = .009) and overall survival (HR 1.52, 95% CI 1.04-2.21; P = .029).  
Conclusions: CSF OPN is a potential biomarker in CNSL. 
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Introduction 
Central nervous system lymphoma (CNSL) arises as primary CNS lymphoma (PCNSL) – a lymphoma 
that is confined to the CNS at time of diagnosis – or as secondary CNS involvement of systemic 
lymphoma (SCNSL) [1-3]. The diagnosis is typically based on contrast-enhanced cranial magnetic 
resonance imaging and histopathological confirmation by a biopsy from a CNS lesion [4]. However, a 
biopsy may be challenging in vulnerable brain regions, and in some cases histological findings are 
inconclusive, particularly after steroid pre-treatment. The utility of cerebrospinal fluid (CSF) 
diagnostics based on tumour cell identification such as conventional CSF cytomorphology, flow 
cytometry [5] or monoclonality assessment by polymerase chain reaction [6] is limited to cases with 
leptomeningeal involvement which is present in approximately 40-50% of SCNSL and in less than 
20% of PCNSL [7, 8]. Identification of reliable diagnostic markers in CSF representing an easily 
accessible compartment is highly desirable to facilitate the diagnosis.  
In the search for diagnostic and prognostic biomarkers for CNSL, microRNA expression patterns in 
the CSF and blood have yielded promising results [9-11]. These studies, however, lacked a 
comparison to other brain tumours. Sasayama et al. reported elevated interleukin-10 in CSF of PCNSL 
patients as compared to patients with other CNS malignancies [12]. Our group detected elevated 
CXCL13 concentration in CSF of 30 PCNSL patients as compared to patients with other CNS 
malignancies and non-malignant CNS diseases [13]. These findings were confirmed in an analysis of 
60 PCNSL and 23 SCNSL samples [14]. Viaccoz et al. identified neopterin, a nonspecific marker of 
CNS inflammation, as possible marker to differentiate PCNSL from other brain tumours [15].  
Osteopontin (OPN) is a proinflammatory cytokine and cell-matrix glycoprotein with numerous 
cellular functions including immune cell activation, B-cell migration and proliferation, chemotaxis, 
cell communication, focal adhesion, and suppression of antitumour immunity [16]. High OPN 
expression is associated with progression, metastatic spread, and poor prognosis in many 
malignancies. Several studies in different human malignancies identified OPN as suitable diagnostic 
and prognostic biomarker [17-24]. In PCNSL, osteopontin (also known as secreted phosphoprotein 1, 
SPP1) is one of the most differentially up-regulated genes as compared to both nodal and extranodal 
non-CNS diffuse large B-cell lymphoma (DLBCL) [25-27]. Immunohistochemical analyses of 
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formalin-fixed, paraffin-embedded tissue previously confirmed high-level expression of OPN in 
PCNSL [25, 26, 28]. In this study, we evaluated the utility of OPN levels in the CSF as a diagnostic 
biomarker for CNSL. 
 
Materials and Methods 
Patients and samples 
CSF samples were obtained prior to chemotherapy by lumbar puncture from 37 immunocompetent 
patients with CNSL: 29 with PCNSL and 8 with SCNSL. Steroid pre-treatment was allowed. Four 
control groups were analysed: (1) 6 patients with inflammatory CNS disease other than multiple 
sclerosis (MS), among them cerebral toxoplasmosis, cerebral sarcoidosis, and unspecified non-
infectious encephalitis, (2) 8 patients with MS, (3) 9 patients with glioblastoma (GBM) and (4) 13 
healthy controls, i.e. patients without CNS disease who underwent diagnostic lumbar puncture for 
peripheral neuropathy or headache, the latter ones to rule out meningitis or subarachnoidal bleeding; 
all of those showed no evidence of CNS disease in the following workup.  
All CSF samples were processed immediately at room temperature by centrifugation for four minutes 
at 4,000 rpm. Supernatants were collected and stored at -80°C. Paired serum samples were collected 
from 17 PCNSL patients, all inflammatory CNS disease patients, and all healthy controls at the time 
of lumbar puncture and stored at -80°C. CSF cell count and protein were analysed in 26 CNSL 
patients, all inflammatory CNS disease patients, and all healthy controls. 
All patients gave written informed consent in accordance with the Declaration of Helsinki and the 
local Institutional Review Board-approved protocols. 
 
Enzyme-linked immunosorbent assay 
OPN concentrations in CSF and serum were determined using the enzyme-linked immunosorbent 
assay (ELISA) from R&D (Quantikine ELISA Human Osteopontin Immunoassay, DOST00; R&D 
Systems Europe, Ltd., Abingdon, UK).  
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Statistical analyses 
Descriptive and explorative data analysis of clinical and ELISA data were performed. Quantitative 
parameters were tested for normal distribution. Distribution of patients’ characteristics was analysed 
by the chi-square test. The Kruskal-Wallis and Mann-Whitney U tests with adjusted P value due to 
Bonferroni correction were used as non-parametric tests to evaluate the quantitative parameters. If not 
stated different, Bonferroni correction was applied with factor 10 (number of pairwise comparisons 
between 5 groups) in analyses with CNSL patients (PCNSL and SCNSL) vs. control groups. 
Bonferroni correction with factor 15 (number of pairwise comparisons between 6 groups) was applied 
in analyses with PCNSL vs. SCNSL vs. control groups. In OPN serum, CSF cell count, and CSF 
protein analyses Bonferroni correction with factor 3 (number of pairwise comparisons between 3 
groups) was used. Comparisons between CSF and serum levels in identical patients were done using 
the Wilcoxon signed rank test. Receiver operating characteristic (ROC) curves were performed on 
levels of CSF OPN. In these curves, for each potential cut-off value of the respective diagnostic 
marker the pair of sensitivity and 1-specificity is determined and plotted vs. each other. The cut-off 
values themselves cannot be read from the curve. The choice of the specific cut-off was done 
according to the criterion of the OPN level at which sensitivity and specificity were most alike. 
Overall survival (OS) and progression-free survival (PFS) were analysed with the Kaplan-Meier-
method for PCNSL patients. PFS was defined as the time from beginning of treatment to first 
progression or death from any cause. OS was defined as the time from beginning of treatment to death. 
Spearman correlations (Spearman correlation coefficient rho = r) were used to quantify the association 
of multifocal brain involvement (3 ordered categories) and CSF OPN level, age and CSF OPN level, 
CSF cell count and CSF OPN level as well as CSF protein and CSF OPN level. To assess the 
prognostic value of CSF OPN in principle, simple and multiple Cox proportional hazard models were 
calculated (“forward” stepwise variable selection with criteria P = .10 (exclusion), P = .05 
(inclusion)). All hazard ratios (HR) refer to a change of 100 units of CSF OPN. 
For statistical analyses IBM SPSS software package, release 22.0, and GraphPad Prism software 
package, release 6.0, were used. 
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Results 
Patient characteristics  
Clinical and histopathological characteristics of CNSL patients are summarised in Table 1. Twenty-
three (79%) PCNSL and five (63%) SCNSL patients had steroid treatment before lumbar puncture. 
An elevated (≥5/µL) CSF cell count was detected in 16 of 26 (62%) patients with CNSL (median 
10.0/µL, range 1.0-14,842.0/µL); total CSF protein was elevated (>45 mg/dL) in 20 (77%) patients 
(median 74.0 mg/dL, range 28.0-341.0 mg/dL). CSF cell count was elevated in one of six (17%) 
patients with inflammatory CNS disease (median 1.7/µL, range 0.3-9.3/µL) and in none of 13 healthy 
controls (median 0.7/µL, range 0.3-2.7/µL). Total CSF protein was elevated in 3 (50%) cases with 
inflammatory CNS disease (median 48.1 mg/dL, range 40.2-64.5 mg/dL) and in one (8%) of the 
healthy controls (median 37.5 mg/dL, range 18.4-49.5 mg/dL).  
CSF cell count was higher in CNSL patients than in patients with inflammatory CNS disease; P < .01 
and healthy controls; P < .01. CSF protein in CNSL patients and patients with inflammatory CNS 
disease showed not significant difference; P = .291, but was higher in CNSL patients than in healthy 
controls; P < .01. 
 
OPN levels in CNSL patients and control groups 
CSF and serum OPN levels of CNSL patients and control groups as well as corresponding P values 
are shown in Figure 1, 2A, and 2B.  
CSF OPN levels did not differ between PCNSL (median 620 ng/mL, range 60-890 ng/mL) and 
SCNSL patients (median 608 ng/mL, range 153-818 ng/mL); P = 1.00. According to the Kruskal-
Wallis test there was a significant difference between the OPN CSF values in CNSL patients and all 
control groups; P < .001. Highest CSF OPN levels were found in PCNSL and SCNSL patients.  
Patients with inflammatory CNS disease (median 356 ng/mL, range 253-531 ng/mL) and healthy 
controls (median 319 ng/mL, range 142-430 ng/mL) showed intermediate CSF OPN levels. Lowest 
CSF OPN levels were seen in MS (median 163 ng/mL, range 29-370 ng/mL) and GBM (median 41 
ng/mL, range 22-191 ng/mL) patients. The median CSF OPN level in all CNSL patients was 620 
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ng/mL (range 60-890 ng/mL) and thus higher than in patients with inflammatory CNS disease; P < 
.05, with MS; P < .01, with GBM; P < .01 and healthy controls; P < .01 (Figure 1).  
In contrast to CSF, median OPN serum levels were low and did not differ between PCNSL patients 
(median 52 ng/mL, range 17-231 ng/mL), patients with inflammatory CNS disease (median 99 ng/mL, 
range 40-273 ng/mL), and healthy controls (median 59 ng/mL, range 22-203 ng/mL); P = .158 (Figure 
2A). The CSF/serum-ratio was predictably higher in PCNSL patients than in patients with 
inflammatory CNS disease or in healthy controls; both P < .01 (Figure 2B). 
Steroid pre-treatment in CNSL patients did not influence CSF OPN level (P = .984). Spearman 
correlation analysis indicates a significant increase of CSF OPN with age in the healthy controls (r = 
.663, P = .014, n = 13), whereas in CNSL patients we did not find such a correlation (r = -.186, P = 
.269, n = 37). CSF OPN did not correlate with CSF cell count (r = -.050 in healthy controls and r = -
.179 in CNSL). Moreover, CSF OPN weakly correlated with total CSF protein in CNSL patients (r = 
.383, P = .053), but not in healthy controls (r = .209, P = .494). 
 
Diagnostic value of CSF OPN 
On the basis of ROC curves, we analysed the diagnostic value of CSF OPN as a diagnostic biomarker 
for CNSL (Figure 3 and Supplementary Figure 1). The area under the ROC curve was .934 (95% 
confidence interval [CI] .873 - .995) for differentiating CNSL from all control patients (cut-off 400 
ng/mL, sensitivity 87%, specificity 86%), .865 (95% CI .745 - .985) for differentiating CNSL from 
inflammatory CNS disease (cut-off 438 ng/mL, sensitivity 84%, specificity 83%), .956 (95% CI .898 - 
1.000) for differentiating CNSL from MS (cut-off 362 ng/mL, sensitivity 89%, specificity 88%), .988 
(95% CI .964 - 1.000) for CNSL vs. GBM patients (cut-off 240 ng/mL, sensitivity 95%, specificity 
100%), and .915 (95% CI .834 - .996) for CNSL vs. healthy controls (cut-off 419 ng/mL, sensitivity 
87%, specificity 85%). 
 
Prognostic value of CSF OPN in patients with PCNSL 
Survival data of 25 PCNSL patients with CSF OPN level measured at time of diagnosis were 
analysed. The median follow-up was 21.4 months. Median PFS and median OS were 26.5 months 
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(95% CI 14.4-38.5 months) and 32.5 months (95% CI 19.2-45.7 months), respectively. In univariate 
analysis, higher level of CSF OPN was significantly associated with shorter PFS (HR 1.47, 95% CI 
1.02-2.10, P = .037), whereas the difference in OS was not significant (HR 1.28, 95% CI .89-1.84; P = 
.187, see also Supplementary Figure 2 with median CSF OPN as cut-off). In multivariate analysis with 
clinical characteristics age and sex, CSF OPN was significantly associated with shorter PFS (HR 1.61, 
95% CI 1.13-2.31, P = .009) and OS (HR 1.52, 95% CI 1.04-2.21; P = .029). Spearman correlation 
analysis revealed a significant correlation between CSF OPN level and multifocal brain involvement (r 
= .460, P = .021). 
 
Discussion 
We provide first evidence that CSF OPN might be a valuable, easy to measure, and cost-effective 
diagnostic and prognostic biomarker in CNSL. ROC analyses revealed that CSF OPN discriminated 
patients with CNSL from control groups with high sensitivity and specificity. In contrast to elevated 
OPN in CSF, serum levels were low and comparable to those of patients with inflammatory CNS 
disease and healthy controls. This indicates that in CNSL patients, high CSF OPN levels are due to 
production and secretion in the CNS and are not the consequence of a systemic inflammation with 
concomitant CNS involvement.  
Due to the rarity of CNSL, very little is known about the mechanisms leading to development of this 
disease in CNS, which is largely devoid of lymphoid tissue. High-levels of proinflammatory proteins 
such as neopterin [15] and - as described in this report - osteopontin may suggest a neuroinflammatory 
process.  First data on gene and protein expression in PCNSL indicate an up-regulation of genes 
associated with cell signalling in extracellular matrix and adhesion related pathways such as DDR1, 
CXCL13, MUM1, TCL1a, CHI3L1 and OPN [25-28]. When OPN expression levels were compared 
between PCNSL, extranodal DLBCL, and nodal DLBCL, an expression was observed in 100% and 
95% in the both first groups compared to 25% in the third group, suggesting its probable role in CNS 
tissue tropism [25]. Moreover, higher CSF OPN levels were found in childhood acute leukaemia with 
CNS involvement than in patients without CNS involvement suggesting a role of OPN as a marker of 
secondary CNS involvement [19]. Since high CSF OPN levels were detected in SCNSL patients, OPN 
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could represent an early marker of secondary CNS involvement in systemic lymphoma. This is worth 
further evaluation considering the low diagnostic value of currently known risk factors to identify 
patients with high risk for secondary CNS involvement in lymphoma [29] and an urgent need for 
markers guiding CNS prophylaxis.  
Numerous studies reported increased CSF OPN levels in patients with MS and other 
neuroinflammatory and neurodegenerative diseases [30-33]. In our study, the median CSF OPN level 
of MS patients was in accordance with data published by others [31, 33]. However, CSF OPN level in 
patients with neuroinflammatory disease, e.g. MS, reflects the extent of inflammation and dynamically 
varies in correlation to activity of disease [30]. Therefore, the median CSF OPN level of our MS 
patients may differ to OPN levels reported by others. 
For GBM, high-level OPN expression has been demonstrated by immunohistochemistry, and 
relatively high OPN levels in CSF of GBM patients were reported in one study [34], which is in 
contrast to our findings. Methodological differences as well as differences in patients’ characteristics 
and pre-treatment might be explanations for the difference to our GBM samples. CSF OPN levels of 
our healthy controls were higher than reported by other studies of patients with childhood acute 
leukaemia without CNS involvement and patients with neurologic symptoms, but without confirmed 
neurologic disease [19, 35, 36]. Although no CNS disease was found in our healthy controls, we 
cannot rule out conditions, as e.g. peripheral neuropathy, with an influence on CSF OPN levels in 
some of them.  
 
In addition to the diagnostic role, OPN may represent an easy to measure prognostic marker in CNSL. 
Patients with higher OPN levels had shorter PFS and OS. Furthermore, higher CSF OPN significantly 
correlated with multifocal brain involvement, which indicates that OPN level reflects tumour burden 
in CNSL. An association of multifocal brain involvement with inferior outcome has previously been 
reported [37, 38]. Moreover, a correlation of increased circulating OPN levels and increased OPN 
expression by tumour cells with an unfavourable prognosis was found in other human malignancies 
[20-22].  
 10 
OPN and its receptor CD44 have been identified as a promising therapeutic target for cancer therapy 
[39, 40]. Considering the generally poor prognosis of CNSL, identifying new targets for more 
effective therapies is highly desirable in this disease. If the contribution of OPN to CNS 
lymphomagenesis is confirmed, evaluation of the inhibition of OPN and/or its receptor as novel 
treatment strategy for CNSL will be worth evaluating. 
A comprehensive overview of previously reported potential biomarkers for PCNSL diagnosis was 
published recently [15]. A combination of OPN with other biomarkers such as IL-10, CXCL13 or 
neopterin could improve diagnostic yield and should be tested. The small sample size, especially of 
the control groups, represents a major limitation of our study. Further studies with larger control 
groups are needed to validate our results. 
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Figure 1. CSF OPN levels in CNSL and control patients. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure legend: Black lines indicate median OPN levels. P values were adjusted by 
Bonferroni correction for multiple comparisons. CSF...cerebrospinal fluid, 
OPN...osteopontin, CNSL...central nervous system lymphoma (primary and secondary), 
PCNSL...primary CNSL, SCNSL...secondary CNS involvement of systemic lymphoma, 
ICD…inflammatory CNS disease, MS…multiple sclerosis, GBM...glioblastoma.  
One of the PCNSL patient had considerably low CSF OPN level compared to all other 
PCNSL patients. In this patient, PCNSL had formerly been diagnosed and treated and CSF 
was obtained at time of relapse, which was assumed only by clinical and radiological 
characteristics. As histological results from time of relapse were not conclusive, we cannot 
definitely be certain of PCNSL diagnosis in this patient.   
 
 
 
 
Comparison P value 
PCNSL vs. SCNSL = 1.00 
CNSL vs. ICD < .05 
CNSL vs. MS < .01 
CNSL vs. GBM < .01 
CNSL vs. healthy controls < .01 
ICD vs. MS = .05 
ICD vs. GBM < .01 
ICD vs. healthy controls = 1.00 
MS vs. GBM = .15 
MS vs. healthy controls = .08 
GBM vs. healthy controls < .01 
Figure 2. A) CSF and serum OPN levels in PCNSL and control patients, B) CSF/serum-ratio in PCNSL 
and control patients. 
A) B) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legend: *…P < .05, **…P < .01, ***…P < .001, n.s….not significant. Black lines indicate median 
OPN levels. P values in Figure 2 B) were adjusted by Bonferroni correction for multiple comparisons. 
CSF...cerebrospinal fluid, OPN...osteopontin, PCNSL...primary central nervous system lymphoma, 
CNS…central nervous system. 
 
 
 
Figure 3. ROC curve analyses of CSF OPN levels. 
 
 
Figure legend: ROC…receiver operating characteristic, CSF...cerebrospinal fluid, 
OPN...osteopontin, CNSL...central nervous system lymphoma (primary and secondary), 
ICD…inflammatory CNS disease, MS…multiple sclerosis, GBM...glioblastoma, AUC…area under 
the curve, CI…confidence interval. 
 
 
Table 1. Clinical characteristics in CNSL patients and control groups.  
 CNSL (n=37) PCNSL (n=29) SCNSL (n=8) ICD (n=6) MS (n=8) GBM (n=9) Healthy 
controls (n=13) 
        
Median age, years (range) 65 (43-84) 65 (43-84) 66 (47-75) 58 (42-69) 45 (31-60) 58 (45-75) 53 (23-81) 
Males (%) 17 (46) 13 (45) 4 (50) 3 (50) 3 (38) 5 (56)  8 (62) 
        Histopathological diagnosis (%)        
DLBCL 32 (86) 27 (93) 5 (63) n.a. n.a. n.a. n.a. 
Mantle cell lymphoma 1 (3) 0 1 (13) n.a. n.a. n.a. n.a. 
Follicular lymphoma 1 (3) 0 1 (13) n.a. n.a. n.a. n.a. 
Other low-grade B-cell lymphoma 1 (3) 0 1 (13) n.a. n.a. n.a. n.a. 
B-cell lymphoma without further 
specification 
1 (3) 1 (4) 0 n.a. n.a. n.a. n.a. 
No conclusive histological results 1 (3) 1 (4) 0 n.a. n.a. n.a. n.a. 
        Localisation of CNS manifestation (%)        
Brain parenchyma only 32 (86) 27 (93) 5 (63) n.a. n.a. n.a. n.a. 
Brain parenchyma and eye 2 (5) 2 (7) 0 n.a. n.a. n.a. n.a. 
Brain parenchyma and CSF 1 (3) 0 1 (13) n.a. n.a. n.a. n.a. 
CSF only 2 (5) 0 2 (25) n.a. n.a. n.a. n.a. 
        CSF cell count n=26 n=22 n=4 n=6 n.d. n.d. n=13 
Elevated CSF cell count (≥5/µL) (%) 16 (62) 13 (59) 3 (75) 1 (17) n.d. n.d. 0 
Median CSF cell count, /µL (range) 10 (1-14.842) 9 (1-230) 44 (4-14.842) 2 (0-9) n.d. n.d. 1 (0-3) 
        CSF protein n=26 n=22 n=4 n=6 n.d. n.d.  n=13 
Elevated CSF protein (>45 mg/dL) (%) 20 (77) 16 (73) 4 (100) 3 (50) n.d. n.d. 1 (8) 
Median CSF protein, mg/dL (range) 74 (28-341) 62 (28-341) 204 (76-258) 48 (40-65) n.d.  n.d. 38 (18-50) 
 
Table legend: CNSL…central nervous system lymphoma, DLBCL... diffuse large B-cell lymphoma, CSF...cerebrospinal fluid, PCNSL...primary central nervous system 
lymphoma, SCNSL...secondary CNS involvement of systemic lymphoma, ICD…inflammatory CNS disease, MS…multiple sclerosis, GBM...glioblastoma n.a.…not 
applicable, n.d….not done. 
Supplementary Figure 1. ROC curve analysis of CSF OPN levels (CNSL vs. all control groups). 
 
 
Figure legend: ROC…receiver operating characteristic, CSF...cerebrospinal fluid, 
OPN...osteopontin, CNSL...central nervous system lymphoma (primary and secondary), AUC…area 
under the curve, CI…confidence interval. 
 
 
Supplementary Figure 2. Comparison of progression-free survival and overall survival according to 
CSF OPN expression (cut-off = median CSF OPN). 
 
 
 
 
 
  > Median, n = 12 
 < Median,  n = 13 
P = .014 
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 < Median,  n = 13 
P = .139 
